Figure 1. Summary of somatic mutations identified in the 50 NSCLC patients.

1. Detection of tumour EGFR mutations in plasma. EGFR mutation status in tumour samples was documented in the clinical record for 43 patients (Appendix Table S1), of which 38 had verified hotspot activating mutations (deletion in exon 19 for 23 patients and the L858R mutation for 15 patients), three patients had other mutations in EGFR (one of these patients had two different mutations detected in the tumour sample), and two patients were wild‐type for EGFR according to tumour analysis and confirmed by plasma analysis.
2. Summary of the mutations identified in any of the plasma samples during longitudinal follow‐up in the 50 patients. TKI‐naïve (n = 34) and TKI‐treated (n = 16) patients are presented separately.